Cartesian Therapeutics Business Summary

Cartesian Therapeutics, Inc. (RNAC) is a clinical-stage biotechnology company pioneering mRNA-engineered cell therapies for autoimmune diseases. The company generates revenue primarily through strategic collaborations, licensing agreements, and milestone payments, though it currently operates as a pre-commercial entity supported by substantial institutional capital and a cash runway extending into mid-2027. Its primary business segments are centered on its proprietary "RNA Armory" platform, which enables the large-scale manufacturing of autologous and allogeneic RNA CAR-T cells. The lead candidate, Descartes-08, is currently in Phase 3 clinical trials for generalized myasthenia gravis (MG) and Phase 2 for myositis. Cartesian competes directly with clinical-stage biotechs such as Astria Therapeutics, Kura Oncology, and Prime Medicine; however, it distinguishes itself by offering a "curing without conditioning" approach, utilizing mRNA to avoid the genomic integration and toxic preconditioning chemotherapy required by traditional DNA-based CAR-T competitors. The company was founded by Dr. Murat Kalayoglu and Dr. Michael Singer, a duo with a successful pedigree of building and exiting life science ventures like HealthHonors and Topokine. The current leadership team is led by President and CEO Dr. Carsten Brunn, formerly the President of Pharmaceuticals for the Americas at Bayer and CEO of Selecta Biosciences. Key executives include CFO Blaine Davis, Chief Medical Officer Dr. Miloš Miljković (formerly of the National Cancer Institute), and Chief Scientific Officer Dr. Christopher Jewell. While former CTO Dr. Metin Kurtoglu transitioned to a consultant role in 2025, the technical strategy remains overseen by the core executive suite. Notable board members and investors include Dr. Timothy Springer, a renowned Harvard immunologist and major shareholder, along with institutional backing from BlackRock, Vanguard, and FMR LLC (Fidelity).